Get the Stockscreener App
1.71
4.47%
-0.08
After Hours:
1.64
-0.07
-4.09%
Dogwood Therapeutics Inc stock is traded at $1.71, with a volume of 712.11K.
It is down -4.47% in the last 24 hours and down -44.12% over the past month.
Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
See More
Previous Close:
$1.79
Open:
$1.72
24h Volume:
712.11K
Relative Volume:
10.62
Market Cap:
$57.12M
Revenue:
-
Net Income/Loss:
$-34.26M
P/E Ratio:
-0.0904
EPS:
-18.9056
Net Cash Flow:
$-15.62M
1W Performance:
-11.86%
1M Performance:
-44.12%
6M Performance:
-71.74%
1Y Performance:
-58.89%
1-Day Range:
$1.6246
$1.81
1-Week Range:
$1.6246
$2.17
52-Week Range:
$1.6246
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
Name
Dogwood Therapeutics Inc
Sector
Industry
Phone
(866) 620-8655
Address
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
1.71 | 59.79M | 0 | -34.26M | -15.62M | -18.91 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dogwood Therapeutics Inc Stock (DWTX) Latest News
Dogwood Therapeutics receives FDA clearance for SP16 pain trial By Investing.com - Investing.com South Africa
Dogwood Therapeutics Announces FDA Acceptance of SP16 - GlobeNewswire
Decliners Report: How volatile is Dogwood Therapeutics Inc stock2026 Market WrapUp & AI Driven Stock Movement Reports - baoquankhu1.vn
Will Dogwood Therapeutics Inc benefit from government policyCEO Change & Weekly Stock Performance Updates - baoquankhu1.vn
Investment Report: Will Dogwood Therapeutics Inc benefit from geopolitical trends2026 Institutional & Breakout Confirmation Trade Signals - baoquankhu1.vn
Published on: 2026-04-11 05:48:42 - baoquankhu1.vn
Activity Recap: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Performance Recap: How sensitive is Dogwood Therapeutics Inc to inflationEarnings Summary Report & Proven Capital Preservation Methods - baoquankhu1.vn
Aug Weekly: Should I invest in Dogwood Therapeutics Inc before earnings2026 Key Lessons & Risk Controlled Swing Alerts - baoquankhu1.vn
Downgrade Watch: How sensitive is Dogwood Therapeutics Inc to inflationMarket Sentiment Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Sentiment Watch: What is the PEG ratio of Dogwood Therapeutics IncCEO Change & Smart Allocation Stock Tips - baoquankhu1.vn
Dogwood Therapeutics Reports Q1 2026 Progress: Advances in Halneuron® and SP16 for Cancer-Related Pain and Neuropathy, $12.5M Raised - Minichart
Analysts Issue Forecasts for DWTX Q1 Earnings - Defense World
Dogwood Therapeutics Highlights Pipeline Progress and Extended Runway - TipRanks
Dogwood Therapeutics (NASDAQ: DWTX) details non-opioid pain pipeline in Q1 2026 update - Stock Titan
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Q1 Earnings Estimate for DWTX Issued By Zacks Research - MarketBeat
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron Results Expected in 3Q26 - Research Tree
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26 - Yahoo Finance
US Market Recap: What is the long term forecast for Dogwood Therapeutics Inc stockWeekly Profit Recap & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Monday - MarketBeat
HC Wainwright Issues Positive Forecast for DWTX Earnings - MarketBeat
If You Invested $1,000 in Dogwood Therapeutics (DWTX) - Stock Titan
History Review: Will Dogwood Therapeutics Inc benefit from government policyTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Aug Decliners: Will Dogwood Therapeutics Inc benefit from government policyPortfolio Profit Report & Daily Chart Pattern Signals - baoquankhu1.vn
What is HC Wainwright’s Estimate for DWTX FY2030 Earnings? - Defense World
What is HC Wainwright's Estimate for DWTX FY2030 Earnings? - MarketBeat
Performance Recap: Is Dogwood Therapeutics Inc stock showing strong momentum - baoquankhu1.vn
Dogwood Therapeutics 2025 Annual Report – Pipeline, Clinical Progress, Intellectual Property, and Risks in Neuropathic Pain Drug Development - Minichart
Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates - AlphaStreet
Moving Averages: Is Dogwood Therapeutics Inc stock showing strong momentum2026 Short Interest & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Dogwood Therapeutics (DWTX) details Halneuron pain program and going-concern risk - Stock Titan
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
DWTX: Halneuron® Phase 2b trial advances, with funding secured through key 2026 milestones - TradingView
Dogwood Therapeutics (Nasdaq: DWTX) ramps R&D and extends cash runway - Stock Titan
Dogwood Therapeutics Q4 net loss narrows on lower expenses - TradingView
Dogwood Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Short Interest in Dogwood Therapeutics, Inc (NASDAQ:DWTX) Decreases By 15.1% - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 1.7%Time to Buy? - MarketBeat
Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal - The Globe and Mail
Dogwood Therapeutics, Inc. 8-K SEC Filing March 11, 2026: Company Information, Stock, and Key Details - Minichart
Dogwood Therapeutics (Nasdaq: DWTX) holders back major warrant exercise - Stock Titan
CK Life Sciences Establishes Sequencio Therapeutics to Advance Therapeutic Cancer Vaccines Development - The Manila Times
Sentiment Watch: What is the long term forecast for Dogwood Therapeutics Inc stockTrend Reversal & Accurate Buy Signal Alerts - baoquankhu1.vn
Maxim Group Sticks to Its Buy Rating for Dogwood Therapeutics (DWTX) - The Globe and Mail
Dogwood Therapeutics (DWTX) CMO receives grant of 82,500 stock options - Stock Titan
Dogwood Therapeutics (DWTX) SVP awarded 82,500-share stock option grant - Stock Titan
DWTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bull Run: Does Dogwood Therapeutics Inc stock benefit from AI growthJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Shorts Report: Is Dogwood Therapeutics Inc stock showing strong momentumDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Aug Update: Does Dogwood Therapeutics Inc stock benefit from AI growthWeekly Stock Summary & Reliable Breakout Forecasts - baoquankhu1.vn
Dogwood Therapeutics Inc Stock (DWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):